Table 2.
Age and study site-adjusted correlation of 37 top metabolites with scores on the Scale of Aging Vigor in Epidemiology (SAVE) (p < 0.05) and attenuations after further adjustments among 287 black men from the Health, Aging, and Body Composition study.
| Log-Transformed and Standardized Metabolites |
Human Metabolome Database ID Number |
Human Metabolome Database Taxonomy Sub Class |
Continuous SAVE Scores, Adjusting for Age and Study Site (N = 287) |
Continuous SAVE Scores, Adjusting for Multiple Variables 1 (n = 257) |
||
|---|---|---|---|---|---|---|
| Correlation, p-Value | False Discovery Rate | Correlation, p-Value | Percent Attenuation 2 |
|||
| Glucuronate | HMDB00127 | Carbohydrates/carbohydrate conjugates | 0.21, p = 0.0003 | 0.08 | 0.12, p = 0.07 | 49% |
| Tryptophan | HMDB00929 | Indolyl carboxylic acids/derivatives | −0.21, p = 0.0005 | 0.08 | −0.18, p = 0.005 | 15% |
| Methionine | HMDB00696 | Amino acids/peptides/analogues | −0.19, p = 0.001 | 0.15 | −0.13, p = 0.04 | 16% |
| N-carbamoyl-beta-alanine | HMDB00026 | Ureas | 0.17, p = 0.004 | 0.22 | 0.13, p = 0.045 | 39% |
| Tyrosine | HMDB00158 | Amino acids/peptides/analogues | −0.17, p = 0.004 | 0.22 | −0.16, p = 0.01 | −5% |
| Isocitrate | HMDB00193 | Tricarboxylic acids and derivatives | 0.17, p = 0.004 | 0.22 | 0.11, p = 0.08 | 40% |
| Creatinine | HMDB00562 | Amino acids/peptides/analogues | 0.16, p = 0.008 | 0.27 | 0.02, p = 0.79 | 89% |
| C4-OH carnitine | HMDB13127 | Beta hydroxy acids/derivatives | 0.16, p = 0.009 | 0.27 | 0.10, p = 0.14 | 34% |
| C14:0 SM | HMDB12097 | Phosphosphingolipids | −0.15, p = 0.009 | 0.27 | −0.14, p = 0.03 | −6% |
| Cystathionine | HMDB00099 | Amino acids/peptides/analogues | 0.15, p = 0.009 | 0.27 | 0.11, p = 0.09 | 32% |
| Hydroxyphenylacetate | HMDB00020 | 1-hydroxy-2-unsubstituted benzenoids | 0.15, p = 0.01 | 0.27 | −0.004, p = 0.95 | 103% |
| Putrescine | HMDB01414 | Amines | 0.15, p = 0.01 | 0.27 | 0.11, p = 0.09 | 16% |
| 1-methylnicotinamide | HMDB00699 | Pyridinecarboxylic acids/derivatives | −0.15, p = 0.01 | 0.27 | −0.18, p = 0.004 | −25% |
| Asparagine | HMDB00168 | Amino acids/peptides/analogues | −0.15, p = 0.01 | 0.27 | −0.12, p = 0.07 | 13% |
| Leucine | HMDB00687 | Amino acids/peptides/analogues | −0.14, p = 0.02 | 0.35 | −0.19, p = 0.003 | −34% |
| 5-aminolevulinic acid | HMDB01149 | Amino acids/peptides/analogues | 0.14, p = 0.02 | 0.36 | −0.02, p = 0.81 | 113% |
| Inosine | HMDB00195 | Not available | 0.14, p = 0.02 | 0.39 | 0.12, p = 0.06 | 16% |
| Histidine | HMDB00177 | Amino acids/peptides/analogues | −0.13, p = 0.03 | 0.39 | −0.12, p = 0.07 | 4% |
| C34:3 PE plasmalogen | HMDB11343 | Glycerophosphoethanolamines | −0.13, p = 0.03 | 0.39 | −0.08, p = 0.21 | −15% |
| Symmetric dimethylarginine (SDMA) | HMDB03334 | Amino acids/peptides/analogues | 0.13, p = 0.03 | 0.39 | 0.02, p = 0.77 | 86% |
| C24:1 ceramide (d18:1) | HMDB04953 | Ceramides | 0.13, p = 0.03 | 0.39 | 0.12, p = 0.06 | −7% |
| C36:4 PE | HMDB08937 | Glycerophosphoethanolamines | 0.13, p = 0.03 | 0.39 | 0.07, p = 0.31 | 43% |
| Urate | HMDB00289 | Purines/purine derivatives | 0.13, p = 0.03 | 0.39 | 0.11, p = 0.09 | 21% |
| C18:2 CE | HMDB00610 | Steroid esters | −0.13, p = 0.03 | 0.39 | −0.09, p = 0.17 | 22% |
| Trimethylamine-N-oxide | HMDB00925 | Aminoxides | 0.13, p = 0.03 | 0.39 | 0.02, p = 0.73 | 80% |
| 2-hydroxyglutarate | HMDB00694 | Short-chain hydroxy acids/derivatives | 0.13, p = 0.03 | 0.39 | 0.07, p = 0.29 | 49% |
| C24:0 SM | HMDB11697 | Phosphosphingolipids | −0.13, p = 0.03 | 0.39 | −0.13, p = 0.049 | −3% |
| Fumarate | HMDB00134 | Dicarboxylic acids/derivatives | 0.13, p = 0.03 | 0.39 | 0.19, p = 0.002 | −7% |
| C22:0 SM | HMDB12103 | Phosphosphingolipids | −0.13, p = 0.03 | 0.39 | −0.15, p = 0.02 | −10% |
| C20:5 LPC | HMDB10397 | Glycerophosphocholines | −0.12, p = 0.04 | 0.39 | −0.06, p = 0.36 | 40% |
| Salicylurate | HMDB00840 | Benzoic acids/derivatives | 0.12, p = 0.04 | 0.41 | −0.02, p = 0.75 | 118% |
| Homogentisate | HMDB00130 | Phenylacetic acids | 0.12, p = 0.04 | 0.41 | 0.08, p = 0.19 | 45% |
| Glycodeoxycholate | HMDB00631 | Bile acids, alcohols and derivatives | −0.12, p = 0.04 | 0.42 | −0.13, p = 0.045 | −13% |
| Malate | HMDB00156 | Beta hydroxy acids and derivatives | 0.12, p = 0.04 | 0.42 | 0.16, p = 0.01 | −9% |
| 5-hydroxytryptophan | HMDB00472 | Tryptamines and derivatives | −0.12, p = 0.04 | 0.42 | −0.10, p = 0.13 | 31% |
| C54:10 TAG | ---- | Triradylcglycerols | −0.12, p = 0.046 | 0.43 | −0.16, p = 0.01 | −23% |
| C44:13 PE plasmalogen | ---- | Glycerophosphoethanolamines | −0.12, p = 0.049 | 0.44 | −0.07, p = 0.29 | 23% |
1 Current smoking status, body mass index, appendicular lean mass, percent body fat, daily protein intake, interleukin-6, C-reactive protein, creatinine, cardiovascular disease, diabetes, pulmonary diseases, and total number of prescription medications. 2 Percent attenuation = 100*(r1−r2)/r1; where r1 = correlation coefficient between SAVE scores and a metabolite, adjusting for age and study site, r2 = correlation coefficient after further adjustments. Note: 30 participants were missing appendicular lean mass, percent body fat, daily protein intake, interleukin-6, C-reactive protein, and/or creatinine, thus, the correlation coefficient that was further adjusted for those variables was compared to the age- and study site-adjusted correlation coefficient restricted to the same sample size to calculate percent attenuation. Grey shading indicates metabolites that were significant (p < 0.05) after adjusting for multiple more commonly measured variables. SM = sphingomyelin. PE = phosphatidylethanolamine. CE = cholesteryl ester. LPC = lysophosphatidylcholine. TAG = triacylglycerol.